Effects of oral estrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis in apoE-deficient mice

Lih Yuh Chen Wing, Ya Chi Chen, Yu Yin Shih, Jung Chien Cheng, Yiu Jiuan Lin, Meei Jyh Jiang

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The effect of hormone replacement therapy (HRT) on cardiovascular diseases remains controversial. Studies conducted on postmenopausal women indicate that oral HRT increases risk factors that may counteract the atheroprotective effect of estrogen. However, the effects of estrogen on atherosclerosis have been examined using subcutaneous estrogen in most animal studies, which points to the need for evaluating the effect of oral estrogen. Reactive oxygen species (ROS) have emerged as critical factors in the pathogenesis of atherosclerosis. This study examined the effect of long-term oral estrogen treatment on aortic oxidative stress and atherosclerosis in female apoE-/- mice to mimic HRT in humans. Ovariectomized apoE-/- mice were given 6 μg/day of oral 17β-estradiol (E2) or control vehicle for 12 weeks. Estrogen treatment reduced atherosclerotic lesions by 38% (E2: 0.20 ± 0.01 mm2/section; control vehicle: 0.32 ± 0.02 mm2/section) and intima by 32% (E2: 0.44 ± 0.02 mm2/section; control vehicle: 0.65 ± 0.04 mm 2/section) in the aortic root. Serum levels of total and low-density lipoprotein cholesterol were significantly decreased after estrogen treatment. Aortic superoxide anion levels and the expression of NAD(P)H oxidase subunit p22phox markedly decreased, and two ROS scavenging enzymes, Cu/ZnSOD and MnSOD, were upregulated after estrogen treatment. Estrogen at physiological concentration inhibited tumor necrosis factor-α-stimulated NAD(P)H oxidase activity in both cultured smooth muscle cells and peritoneal macrophages. These results showed that longterm oral estrogen treatment reduces ROS levels and atherosclerosis progression in apoE-/- mice. Oral estrogen alters ROS-generating and -scavenging enzyme expression, suggesting that anti-oxidative actions in the vessel wall contribute to atheroprotective effects of estrogen.

Original languageEnglish
Pages (from-to)1037-1046
Number of pages10
JournalExperimental Biology and Medicine
Volume234
Issue number9
DOIs
Publication statusPublished - 2009 Sep 1

Fingerprint

Scavenging
Apolipoproteins E
Reactive Oxygen Species
Atherosclerosis
Estrogens
Enzymes
Hormone Replacement Therapy
NADPH Oxidase
Hormones
Therapeutics
Oxidative stress
Macrophages
Peritoneal Macrophages
Superoxides
LDL Cholesterol
Smooth Muscle Myocytes
Muscle
Estradiol
Animals
Oxidative Stress

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wing, Lih Yuh Chen ; Chen, Ya Chi ; Shih, Yu Yin ; Cheng, Jung Chien ; Lin, Yiu Jiuan ; Jiang, Meei Jyh. / Effects of oral estrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis in apoE-deficient mice. In: Experimental Biology and Medicine. 2009 ; Vol. 234, No. 9. pp. 1037-1046.
@article{e976dfedb60f4ac299c99a9ced87f87b,
title = "Effects of oral estrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis in apoE-deficient mice",
abstract = "The effect of hormone replacement therapy (HRT) on cardiovascular diseases remains controversial. Studies conducted on postmenopausal women indicate that oral HRT increases risk factors that may counteract the atheroprotective effect of estrogen. However, the effects of estrogen on atherosclerosis have been examined using subcutaneous estrogen in most animal studies, which points to the need for evaluating the effect of oral estrogen. Reactive oxygen species (ROS) have emerged as critical factors in the pathogenesis of atherosclerosis. This study examined the effect of long-term oral estrogen treatment on aortic oxidative stress and atherosclerosis in female apoE-/- mice to mimic HRT in humans. Ovariectomized apoE-/- mice were given 6 μg/day of oral 17β-estradiol (E2) or control vehicle for 12 weeks. Estrogen treatment reduced atherosclerotic lesions by 38{\%} (E2: 0.20 ± 0.01 mm2/section; control vehicle: 0.32 ± 0.02 mm2/section) and intima by 32{\%} (E2: 0.44 ± 0.02 mm2/section; control vehicle: 0.65 ± 0.04 mm 2/section) in the aortic root. Serum levels of total and low-density lipoprotein cholesterol were significantly decreased after estrogen treatment. Aortic superoxide anion levels and the expression of NAD(P)H oxidase subunit p22phox markedly decreased, and two ROS scavenging enzymes, Cu/ZnSOD and MnSOD, were upregulated after estrogen treatment. Estrogen at physiological concentration inhibited tumor necrosis factor-α-stimulated NAD(P)H oxidase activity in both cultured smooth muscle cells and peritoneal macrophages. These results showed that longterm oral estrogen treatment reduces ROS levels and atherosclerosis progression in apoE-/- mice. Oral estrogen alters ROS-generating and -scavenging enzyme expression, suggesting that anti-oxidative actions in the vessel wall contribute to atheroprotective effects of estrogen.",
author = "Wing, {Lih Yuh Chen} and Chen, {Ya Chi} and Shih, {Yu Yin} and Cheng, {Jung Chien} and Lin, {Yiu Jiuan} and Jiang, {Meei Jyh}",
year = "2009",
month = "9",
day = "1",
doi = "10.3181/0811-RM-332",
language = "English",
volume = "234",
pages = "1037--1046",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "9",

}

Effects of oral estrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis in apoE-deficient mice. / Wing, Lih Yuh Chen; Chen, Ya Chi; Shih, Yu Yin; Cheng, Jung Chien; Lin, Yiu Jiuan; Jiang, Meei Jyh.

In: Experimental Biology and Medicine, Vol. 234, No. 9, 01.09.2009, p. 1037-1046.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of oral estrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis in apoE-deficient mice

AU - Wing, Lih Yuh Chen

AU - Chen, Ya Chi

AU - Shih, Yu Yin

AU - Cheng, Jung Chien

AU - Lin, Yiu Jiuan

AU - Jiang, Meei Jyh

PY - 2009/9/1

Y1 - 2009/9/1

N2 - The effect of hormone replacement therapy (HRT) on cardiovascular diseases remains controversial. Studies conducted on postmenopausal women indicate that oral HRT increases risk factors that may counteract the atheroprotective effect of estrogen. However, the effects of estrogen on atherosclerosis have been examined using subcutaneous estrogen in most animal studies, which points to the need for evaluating the effect of oral estrogen. Reactive oxygen species (ROS) have emerged as critical factors in the pathogenesis of atherosclerosis. This study examined the effect of long-term oral estrogen treatment on aortic oxidative stress and atherosclerosis in female apoE-/- mice to mimic HRT in humans. Ovariectomized apoE-/- mice were given 6 μg/day of oral 17β-estradiol (E2) or control vehicle for 12 weeks. Estrogen treatment reduced atherosclerotic lesions by 38% (E2: 0.20 ± 0.01 mm2/section; control vehicle: 0.32 ± 0.02 mm2/section) and intima by 32% (E2: 0.44 ± 0.02 mm2/section; control vehicle: 0.65 ± 0.04 mm 2/section) in the aortic root. Serum levels of total and low-density lipoprotein cholesterol were significantly decreased after estrogen treatment. Aortic superoxide anion levels and the expression of NAD(P)H oxidase subunit p22phox markedly decreased, and two ROS scavenging enzymes, Cu/ZnSOD and MnSOD, were upregulated after estrogen treatment. Estrogen at physiological concentration inhibited tumor necrosis factor-α-stimulated NAD(P)H oxidase activity in both cultured smooth muscle cells and peritoneal macrophages. These results showed that longterm oral estrogen treatment reduces ROS levels and atherosclerosis progression in apoE-/- mice. Oral estrogen alters ROS-generating and -scavenging enzyme expression, suggesting that anti-oxidative actions in the vessel wall contribute to atheroprotective effects of estrogen.

AB - The effect of hormone replacement therapy (HRT) on cardiovascular diseases remains controversial. Studies conducted on postmenopausal women indicate that oral HRT increases risk factors that may counteract the atheroprotective effect of estrogen. However, the effects of estrogen on atherosclerosis have been examined using subcutaneous estrogen in most animal studies, which points to the need for evaluating the effect of oral estrogen. Reactive oxygen species (ROS) have emerged as critical factors in the pathogenesis of atherosclerosis. This study examined the effect of long-term oral estrogen treatment on aortic oxidative stress and atherosclerosis in female apoE-/- mice to mimic HRT in humans. Ovariectomized apoE-/- mice were given 6 μg/day of oral 17β-estradiol (E2) or control vehicle for 12 weeks. Estrogen treatment reduced atherosclerotic lesions by 38% (E2: 0.20 ± 0.01 mm2/section; control vehicle: 0.32 ± 0.02 mm2/section) and intima by 32% (E2: 0.44 ± 0.02 mm2/section; control vehicle: 0.65 ± 0.04 mm 2/section) in the aortic root. Serum levels of total and low-density lipoprotein cholesterol were significantly decreased after estrogen treatment. Aortic superoxide anion levels and the expression of NAD(P)H oxidase subunit p22phox markedly decreased, and two ROS scavenging enzymes, Cu/ZnSOD and MnSOD, were upregulated after estrogen treatment. Estrogen at physiological concentration inhibited tumor necrosis factor-α-stimulated NAD(P)H oxidase activity in both cultured smooth muscle cells and peritoneal macrophages. These results showed that longterm oral estrogen treatment reduces ROS levels and atherosclerosis progression in apoE-/- mice. Oral estrogen alters ROS-generating and -scavenging enzyme expression, suggesting that anti-oxidative actions in the vessel wall contribute to atheroprotective effects of estrogen.

UR - http://www.scopus.com/inward/record.url?scp=70349150593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349150593&partnerID=8YFLogxK

U2 - 10.3181/0811-RM-332

DO - 10.3181/0811-RM-332

M3 - Article

C2 - 19546345

AN - SCOPUS:70349150593

VL - 234

SP - 1037

EP - 1046

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 9

ER -